.png){kind=icon}
.png){kind=icon}
Return
The renaissance of cardiac glycosides in heart failure: why, for whom and when
.png){kind=icon}
PRE
AI
A
T
DOI：10.1038/s41569-026-01323-6.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Cardiac glycosides were the cornerstone of heart failure treatment for decades, but their use progressively declined after the introduction of modern prognostic medications. Two clinical trials now report that cardiac glycosides can reduce the risk of worsening heart failure events in patients with heart failure with reduced ejection fraction. These results do not mandate a paradigm shift but support a specific role for cardiac glycosides in selected patients.
Journal
IF:
44.2
Papers:
289
Citations:
2.2W
Organization
Cited Papers